U.S. Preventive Services Task Force*
Requests for Single Reprints: Reprints are available from the USPSTF Web site (www.preventiveservices.ahrq.gov) and in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (800-358-9295).
This statement summarizes the current recommendations of the U.S. Preventive Services Task Force (USPSTF) for chemoprevention of breast cancer. The complete USPSTF recommendation and rationale statement on this topic, including a summary of the supporting evidence, is available through the USPSTF Web site (www.preventiveservices.ahrq.gov), the National Guideline Clearinghouse (www.guideline.gov), and in print through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295; e-mail, email@example.com). The complete information on which this statement is based, including evidence tables and references, is available in the accompanying article in this issue and in the summary of the evidence and systematic evidence review on the Web sites already mentioned.
*For a list of the members of the U.S. Preventive Services Task Force, see the Appendix.
Table. Predicted Benefits and Harms of 5 Years of Tamoxifen Therapy according to Age and Family History
Appendix Table 1. U.S. Preventive Services Task Force Grades and Recommendations
Appendix Table 2. U.S. Preventive Services Task Force Grades for Strength of Overall Evidence
U.S. Preventive Services Task Force*. Chemoprevention of Breast Cancer: Recommendations and Rationale. Ann Intern Med. 2002;137:56–58. doi: https://doi.org/10.7326/0003-4819-137-1-200207020-00016
Download citation file:
Published: Ann Intern Med. 2002;137(1):56-58.
Breast Cancer, Guidelines, Hematology/Oncology.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use